Effective board service is a cornerstone of advancing innovation and strategic leadership in healthcare. Through collaborative governance and visionary oversight, we can drive scientific breakthroughs and transform patient outcomes.
— Karen E. Knudsen MBA PhD

Dr. Knudsen’s dedication to excellence is exemplified through her active participation on multiple boards and advisory committees, spanning not-for-profit organizations, biotechnology firms, pharmaceutical companies, and esteemed cancer centers.

Not-for-Profit Organizations

Research!America

Director: 2023–Present

Audit Committee Member: 2023–Present

Association of American Cancer Institutes (AACI)

Director: 2016–2021

President & Chair: 2020–2021

American Association for Cancer Research (AACR)

Director: 2019–2021

Chair, Nominating Committee: 2017–2018

Campaign for Tobacco-Free Kids

Director: 2021–2023

Biotechnology & Pharmaceutical Industry

Exai Bio

Director: 2024–Present

Paradigm Health

Director: 2024–Present

Transcarent

Board Advisor: 2024–Present

ArteraAI

Board Advisor: 2023–Present

CellCentric

Advisor: 2025–Present

Genentech

Scientific Review Board Member: 2019–Present

 

National Cancer Institute (NCI) Designated Cancer Centers

Dr. Knudsen lends her expertise to several NCI-designated cancer centers through their External Advisory Boards:

MD Anderson Comprehensive Cancer Center

Mayo Comprehensive Cancer Center

Moffitt Comprehensive Cancer Center

Northwestern Lurie Comprehensive Cancer Center

UCSF Helen Diller Family Comprehensive Cancer Center

University of Chicago Comprehensive Cancer Center

University of Hawaii Cancer Center

Vice Chair

University of Minnesota Comprehensive Cancer Center

University of New Mexico Comprehensive Cancer Center

Chair